Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients with Myelodysplastic Syndrome BMT CTN @TheBethesdaLabs @nih_nhlbi JCO Precision Oncology Laura Dillon, PhD, FACMG Gege Gui Steven Devine Mitch Horwitz Bart Scott ArcherDX, Inc. ascopubs.org/doi/abs/10.120…

I love this video! Could not have been done without our wonderful, dedicated Network partners

Last day of a great #TCTM21. We will hear about the results of BMT CTN 1301 study today presented by @DrMiguelPerales during LBA session. Hard to believe BMT CTN now nearly 20 years old! Learn more about it's history from our recent review in Journal of Clinical Oncology: ascopubs.org/doi/full/10.12…

Finally an 🍎s to 🍎s comparison of donor sources! MUD clearly > Haplo related = MMUD. Important study that shows matching does matter when controlling for GVHD prophylaxis. 15-MMUD results to be published soon as well.

Did you know that not all marrow transplants requires bone marrow? Peripheral blood stem cells (PBSC) are another option that provide life-saving treatments to patients in need. The PBSC donation process is similar to donating plasma. Want to learn more? ms.spr.ly/6014VWWcn

Post-HCT Cyclophosphamide Boosts Transplant Success medpagetoday.com/hematologyonco…. Nice interview with Dr Bronwen Shaw about @BeTheMatch mismatched URD study recently published in Journal of Clinical Oncology It's about creating good options for all patients regardless of #Race

Increasing Donor Options in Allogenic Hematopoietic Cell Transplantation ascopubs.org/doi/full/10.12… Very nice Journal of Clinical Oncology editorial about @BeTheMatch study that will "rejuvenate" interest in mismatched URD Tx. I agree with Mohamad Mohty and Florent Malard

We are elated that the TRANSPLANT Act passed! And, our advocates are too!💚💙👏👏 Join our #BTMAdvocateAllStars and share with us what renewing our federal Program means to you!

The Center for International Blood and Marrow Transplant Research (CIBMTR) Launches Study of #COVID19 Vaccine Immunogenicity in Patients With Hematological Malignancies Who Have Received #CellularTherapy businesswire.com/news/home/2021…

7/ Conclusions: First study of MGTA-145 + plerixafor in multiple myeloma shows promising efficacy for same day mobilization, well tolerated. Looking forward to completing the study and further development of this agent for improving stem cell mobilization. #ASCO21 #mmsm

GREAT talk from Charlie Craddock CBE this morning MD Anderson Cancer Center. What he has done for allo-transplant for pts w/ AML, not just for the UK, but for the entire field with a coordinated national network facilitating RCTs to answer the most important questions is very special indeed.

Important City of Hope study with encouraging results in MMUDs using PBSC and PTCy. Further rationale for soon to be activated @BeTheMatch NMDP MMUD study called ACCESS. ashpublications.org/bloodadvances/…

Great to be back live ASTCT CRTC. Looking forward to working with the wonderful scholars and great faculty.#ClinicalResearch #bmtsm #tcellrx

Although #BMT is the only known cure for MDS, many people aren’t aware of BMT or think that they’re too old to have one because of its side effects. Learn more about this BMT CTN study: cibmtr.org/ReferenceCente…

Activation alert! #BMTCTN 1903/AMC-109 Auto-RESIST study is open to enrollment: Administration of HIV-specific T cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue clinicaltrials.gov/ct2/show/NCT04… Kieron Dunleavy Steven Devine AMC Operations

#ASH21 Oral: The 𝐔𝐧𝐬𝐭𝐨𝐩𝐩𝐚𝐛𝐥𝐞 CIBMTR @BTMPublicPolicy @BeTheMatch 👏:Neither COVID19, Nor Cryopreservation, Prevented Allogeneic Product Infusion. ✔️9294 collected, 9085 infused ✔️544 ave infused/mo ✔️Recipients of COVID+ donor did not acquire infection Steven Devine

Amazing work by Leslie Kean, MD, PhD and her team, CIBMTR @BeTheMatch and many others for achieving first ever U.S. FDA approval for a drug to prevent acute #GVHD. Historic day for BMT field!

Clinical Impact of Cryopreservation of Allogeneic Hematopoietic Cell Grafts During the Onset of the COVID-19 Pandemic ashpublications.org/bloodadvances/… Our CIBMTR analysis of outcomes of cryopreserved grafts during the pandemic. OS same; but risk of relapse and PGF higher with Cryo.

An incredible amount of work with really brilliant people made #BMTCTN1703 a success and the new SOC for #GvHD prophylaxis #PTCyRules #BMTCTN CIBMTR Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis | NEJM nejm.org/doi/full/10.10…

Proud to share Journal of Clinical Oncology paper of the ACCESS study run by CIBMTR and sponsored by NMDP 145 recipients of MMUD grafts using PTCy experienced outcomes similar to matched transplants, including <7/8 grafts. 59% of patients were diverse!